MedTrace Logo

Study of AFP464 +/- Faslodex in ER + Breast Cancer

NCT01233947 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2012-01-09

No results posted yet for this study

Summary

AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.

Conditions

  • Breast Neoplasm

Interventions

DRUG

AFP464

AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle

DRUG

AFP464 + Faslodex

AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label

Sponsors & Collaborators

  • Tigris Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Joanne L. Blume, M.D. · Texas Oncology-Baylor Charles A. Sammons Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233947 on ClinicalTrials.gov